Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
ProQR Therapeutics today announced virtual poster presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO) held November 13-15, 2020.
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … congenital amaurosis 10 (LCA10) and the investigational RNA therapy for LCA10, sepofarsen experience to date. The … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
… in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited … to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
… to changing lives through the creation of transformative RNA therapies, today provided an update on its ophthalmology … s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA …